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Abstract
Background: Blood pressure (BP) variability is associated with target organ damage in hypertension and diabetes.
The 24 h ambulatory blood pressure monitoring (24 h-ABPM) has been proposed as an evaluation for BP variability
using several indexes [standard deviation (SD) of mean BP, coefficient of variation (CV), BP variation over time
(time-rate index)].
Methods: We evaluated the association between BP variability measured by 24 h-ABPM indexes and echocardiographic
variables in a cross-sectional study in 305 diabetic-hypertensive patients.
Results: Two groups were defined by the median (0.55 mmHg/min) of time-rate systolic BP (SBP) index and
classified as low or high variability. Age was 57.3 ± 6.2 years, 196 (64.3 %) were female. Diabetes duration was
10.0 (5.0–16.2) years, HbA1c was 8.2 ± 1.9 %. Baseline clinical characteristics were similar between low (n = 148)
and high (n = 157) variability groups. Office SBP and systolic 24 h-ABPM were higher in the high variability
group (139.9 mmHg vs 146.0 mmHg, P = 0.006; 128.3 mmHg vs 132.9 mmHg, P = 0.019, respectively). Time-rate
index, SD and CV of SBP, were higher in high variability group (P < 0.001; P < 0.001 and P = 0.003, respectively).
Time-rate index was not independently associated with the echocardiography’s variables in multiple linear model
when adjusting for age, 24 h-ABPM, diabetes duration and HbA1c. The multiple linear regression model revealed that
the significant and independent determinants for septum thickness, relative wall thickness and posterior wall thickness
(parameters of left ventricular hypertrophy) were: age (p = 0.025; p = 0.010; p = 0.032, respectively) and 24 h-SBP
(p < 0.001 in the three parameters).
Conclusion: BP variability estimated by 24 h-ABPM is not independently associated with echocardiographic
parameters in diabetic-hypertensive patients.
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Background
Observational studies had consistently shown the con-
tinuous relationship between office systolic and diastolic
blood pressure (BP) and cardiovascular events [1]. In-
deed, the causal role of high BP for cardiovascular dis-
ease was fully confirmed by clinical trials [2]. The
evidence that high BP highers the risk for cardiovascular
events, and the consistent reduction of these events by
clinical trials of BP-lowering agents are robust proofs of
the concept that high BP is a major cardiovascular deter-
minant [3].
Methods of out-of-office BP measurement such as
24 h ambulatory BP monitoring (24 h-ABPM) evaluated
in general population or in hypertensive-based longitu-
dinal studies also showed a close relationship between
BP elevation and cardiovascular risk [4, 5]. Other param-
eters assessed by 24 h-ABPM, beyond the average of BP,
such as BP variability, may provide additional informa-
tion regarding the cardiovascular risk [6, 7]. Blood pres-
sure fluctuations are a result of the interplay between
external environmental stimuli, vascular environment and
biological autonomic circulatory regulation [8]. Measures
of BP variability can be obtained through different
methods or indexes [9] and short-term BP variability over
a 24 h period estimated from 24 h-ABPM can be mea-
sured by a more refined estimation such as the time-rate
index. This index is calculated as the mean of the absolute
ratios of the differences between successive BP measures
and the time (in minutes) between them. It quantifies how
fast and in which direction systolic BP (SBP) values
change and, thereby, is claimed to offer an insight into
how steep these changes are. Cross-sectional and longitu-
dinal studies showed an independent relationship between
the time-rate index and target-organ damage or cerebro-
vascular events [10–13]. Echocardiographic evaluation is
recommended to assess asymptomatic organ damage in
hypertensive patients since left ventricular hypertrophy
and diastolic dysfunction are independently associated
with cardiovascular outcomes [14]. These variables could
be used as surrogates to assess the possible association be-
tween BP variability and cardiovascular risk in high-risk
patients.
Considering the high cardiovascular risk profile [15]
and the frequent occurrence of autonomic dysfunc-
tion in diabetic patients, [16] the relationship between
the short-term variability over a 24 h period and
target-organ damage should be estimated. This rela-
tionship has not been well evaluated in observational
studies [17]. The present cross-sectional study aims to
address this issue by evaluating the potential associ-
ation between variables of BP variability including the
time-rate index of 24 h-SBP and echocardiographic
parameters of cardiac chambers, left ventricular
hypertrophy and diastolic function.
Methods
This is a cross-sectional study conducted in the out-
patient clinic of a tertiary hospital (Hospital de Clínicas
de Porto Alegre/Brazil), from April 2010 to December
2011. The data came from a larger study that aimed to
assess cardiovascular risk in diabetic hypertensive pa-
tients through non-invasive methods [18–20]. The study
was approved by the Ethics Committee of Porto Alegre
Clinics Hospital (Hospital das Clínicas de Porto Alegre-
GPPG 09–636) which is accredited by the Office of
Human Research Protections as an Institutional Review
Board. All participants signed an informed consent form
before entering the study.
The study population was selected from a consecutive
sample of 2342 screened patients. Patients were included
in this analysis if they had a previous diagnosis of type 2
diabetes mellitus and hypertension, as ascertained by
their personal history of the diseases or because they
were using antidiabetic and/or antihypertensives for
treatment, and were less than 65 years of age. Exclusion
criteria were body mass index (BMI) ≥ 35 kg/m,2 cancer,
arrhythmias (e.g., atrial fibrillation) that could interfere with
BP measurement and 24 h-ABPM recordings. According
to these criteria, 351 patients were included (Fig. 1).
Patients who met the inclusion criteria and agreed to
participate underwent a demographic and clinical base-
line data collection, including the assessment of duration
of diabetes and hypertension and its known chronic
complications, smoking habits, previous cardiovascular
diseases, medication in use, BMI, and office BP levels.
Blood pressure was measured after 15 min of rest with
an automatic sphygmomanometer (OMRON Comfort
III Visomat Incoterm, Germany). High office BP levels
were defined as office BP higher than 140/90 mmHg.
Among the 351 selected individuals, 93.1 % (n = 327)
underwent 24 h-ABPM (Spacelabs 90207, Redmond,
WA) on an usual working day, performed at up to four
months after the initial evaluation (approximately 75 %
of patients had full evaluation within 30 days). Readings
were obtained automatically at 15-min intervals during
the day and at 20-min intervals during the night for the
duration of the 24 h-ABPM period. Cuff size was chosen
according to arm circumference. Daytime was defined as
the interval between 06:00–22:00 h and nighttime was
the interval between 22:00–06:00 h. Individuals with less
than 6 and 18 measures during the night and the day
periods, respectively (n = 24) were excluded from further
analysis. All individuals were instructed to rest or sleep
during the nighttime and to maintain their usual activ-
ities during daytime. Based on the results of the 24 h-
ABPM, the mean 24 h-SBP and diastolic BP (DBP) were
calculated for each patient. We calculated three different
parameters of SBP variability: the standard deviation
of mean (SD), coefficient of variation (CV = SD/mean
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pressure × 100%) and rate of change in SBP over time
(mmHg/min), defined as the first derivative values of SBP
by time (time-rate index). This index allows the calculation
of the sum of angular coefficients and aims to measure
how fast or how slow and which direction SBP values
change. The measure was calculated using the following
formula [9]:




In the formula, r is the rate of BP variability over time
(considering the differences between BP measurements in
each time interval) and N is the number of recordings.
Echocardiography was performed in 98.3 % (n = 345)
of patients by a single investigator, usually on the same
day of the 24 h-ABPM. Images were obtained using a
commercially available instrument (GE Healthcare
VIVID 7, Buckinghamshire, UK) equipped with a 4 MHz
transducer, according to the recommendations of the
American Society of Echocardiography, [21] using three
consecutive cardiac cycles. Standard parasternal and apical
views were performed with subjects in the partial left de-
cubitus position. Left ventricular volumes and ejection frac-
tion were calculated by the Simpson's formula; ventricular
mass was calculated based on wall thickness adjusted in
two ways: to the body surface area and indexed to body
height to the power of 2.7. Relative wall thickness (RWT)
was defined as “septum+ posterior wall (PW) thickness” di-
vided by “left ventricular diastolic diameter”. Diastolic func-
tion was evaluated based upon mitral inflow doppler
measurements (maximum early flow velocity in diastole- E
wave- and maximum late velocity flow in diastole- A wave).
Peak early (E’) and peak late (A’) tissue Doppler velocities
were assessed at the mitral annulus, determining values as
the average of septal and lateral wall measurements. The
variables septum and PW thickness, RWT and left ven-
tricular mass índex were used for categorical analyzes on
the prevalence of left ventricular hypertrophy, adopting the
reference values proposed by the American Society of
Echocardiography [21]. Hypertrophy was defined consider-
ing the normal range of 1.0 cm to septum obtained in a
representative sample of adults in the city of Porto Alegre,
as previously described [22].
Fasting blood samples were collected for laboratory
analysis using commercial kits. Plasma glucose was
evaluated by a glucose oxidase method, serum cre-
atinine by Jaffé’s reaction, and glycated hemoglobin
(HbA1c) by ion-exchange HPLC (Merck-Hitachi L-9100
HbA1c analyzer; reference range 4.8–6.0 %; Merck,
Darmstadt, Germany). Serum total cholesterol and triglyc-
erides were measured by enzymatic-colorimetric methods
(Merck Diagnostica, Germany; Boehringer Mannheim,
Argentina), and High-density lipoprotein (HDL) cholesterol
by a homogeneous direct method (autoanalyzer, ADVIA
1650). Low-density lipoprotein (LDL) cholesterol was cal-
culated using Friedewald’s formula [23]. Glomerular filtra-
tion rate was calculated using the MDRD (Modification of
diet in renal disease) equation [24]. C-Reactive Protein was
measured using an ultrasensitive assay by nephelometry
(Bayer nephelometer, Leverkusen, Germany), capable of
evaluating values in the range of 1–4 mg/l. Urinary albumin
excretion was evaluated by immunoturbidimetry (MICRO-
ALB- AMES Kit, CA, USA). Abnormal albuminuria was
defined as albuminuria of 17 mg/dl or more [25].
Statistical analyses
The comparison groups were defined by the median of
time-rate index of 24 h-SBP and classified as low and high
variability of time-rate index: values ≤ 0.54 mmHg/min or ≥
0.55 mmHg/min, respectively. Comparisons were tested
by Pearson’s chi-square test, Student’s t test, and Mann–
Fig. 1 Flowchart of patient’s selection
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Whitney test. Logistic regression models and multiple lin-
ear regression were used to evaluate the association be-
tween echocardiography’s variables and parameters of
variability of 24 h-SBP. Age, 24 h-SBP, diabetes duration
(years) and HbA1c were included in models. Continuous
variables are expressed as mean ± SD or median and inter-
quartile range. Categorical variables are expressed as num-
ber (%).
Sample size calculation was based upon the mean dif-
ferences in two echocardiographic variables of septum
Table 1 Clinical characteristics of the participants according to blood pressure variability
Characteristics Total sample Low variability High variability P
(n = 305) (n = 148) (n = 157)
Age 57.3 ± 6.2 57.9 ± 6.4 57.5 ± 6.0 0.565
Female gender 196 (64.3) 99 (66.9) 97 (61.8) 0.354
Caucasian 207 (68.3) 99 (66.9) 110 (70.1) 0.334
Duration of diabetes (years) 10 (5 – 16) 10 (5 – 16) 10 (5 – 17) 0.466
Weight 78.3 ± 12.8 79.6 ± 13.6 77.3 ± 12.1 0.116
BMI (kg/m2) 30.1 ± 3.8 30.7 ± 3.9 29.6 ± 3.7 0.013
Waist circumference 102 ± 9 103 ± 10 101 ± 91 0.203
Neck circumference 38.5 ± 3.5 38.5 ± 3.3 38.6 ± 3.7 0.874
Smoking
No 163 (33.4) 81 (55.9) 82 (52.2) 0.803
Yes 38 (12.6) 18 (12.4) 20 (12.7)
Former 101 (54) 46 (31.7) 55 (35.0)
With any previous cardiovascular comorbiditya 70 (23) 31 (20.9) 39 (24.8) 0.404
Abnormal albuminuriab 88 (28.9) 43 (29.0) 45 (28.7) 0.520
Myocardial infarction 38 (12.6) 16 (11.0) 22 (14.1) 0.410
Coronary artery bypass grafting 13 (4.3) 4 (2.8) 9 (5.8) 0.199
PCI 25 (8.3) 9 (6.3) 16 (10.3) 0.210
Heart failure 26 (8.7) 15 (10.3) 11 (7.1) 0.318
Stroke 28 (9.5) 19 (13.5) 9 (5.8) 0.024
Medications
Insulin 143 (47.2) 58 (39.5) 85 (54.5) 0.009
1 Antihypertensive drug 50 (16.4) 22 (14.9) 28 (17.8) 0.537
2 Antihypertensive drug 87 (28.5) 38 (25.7) 49 (31.2) 0.311
≥3 Antihypertensive drug 168 (55.1) 88 (59.5) 80 (51) 0.167
Antiplatelet 199 (65.9) 101 (68.7) 98 (63.2) 0.315
Statins 210 (69.8) 113 (76.9) 97 (63) 0.009
Laboratory characteristics
HbA1c (%) 8.2 ± 1.9 8.2 ± 1.9 8.3 ± 1.9 0.743
Fasting plasma glucose (mg/dL) 159.3 ± 72.4 162.2 ± 74.8 156.7 ± 70.4 0.533
Total cholesterol (mg/dL) 178.8 ± 42.4 176.6 ± 38.7 180.7 ± 45.6 0.426
HDL cholesterol (mg/dL) 41.9 ± 11.8 42.1 ± 12.3 41.8 ± 11.4 0.793
Triglycerides (mg/dL) 155 (103.8 – 234) 152 (103 – 216) 163 (104 – 248) 0.534
GFR (mL/min/1.73 m2) 90.4 ± 26.8 89.1 ± 26.4 91.7 ± 27.2 0.401
The comparison groups were defined by the median of time-rate index of 24 h systolic BP and classified as low and high variability of time-rate index: values ≤ 0.54
or≥ 0.55, respectively
BMI body mass index; PCI percutaneous coronary intervention; GFR estimated glomerular filtration rate calculated by the MDRD equation; BP: blood pressure
aWith previous cardiovascular comorbidity = when reported at least one previous cardiovascular disease (Myocardial infarction; Coronary artery bypass grafting;
PCI; Heart failure; Stroke)
bAbnormal albuminuria, defined by albuminuria >17 mg/L
Continuous variables are expressed as mean ± standard deviation or median (interquartile range (p25-p75)). Categorical variables are expressed as number (%).
Comparisons (low variability vs. high variability) were tested by Pearson’s χ2 test, Student t test and Mann–Whitney test
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and E/E’, between low and high variability. Considering
the 1:1 proportion in low and high variability groups, a
SD of 0.17 cm, an alpha error of 5 %, and power of 90 %
to detect a 10 % increase in the septum, the sample size
estimation was 124 patients (62 in each group). For the
E/E’ ratio we considered a SD of 3.6, considering the
same proportion, alpha error and power to detect a 15 %
of difference between groups, the sample size estimation
was 162 patients (81 in each group).
Logarithmic transformation was applied to albuminuria
before parametric tests were applied. P values < 0.05 (two-
tailed) were considered to be statistically significant. Statis-
tical Package for Social Science (SPSS, Chicago, IL.) version
18.0 was used for the analyses.
Results
A total of 305 patients was evaluated. The characteristics
of the subjects studied, grouped as low and high variabil-
ity (time-rate index of 24 h-SBP) are presented in
Table 1. Patients were 57.3 ± 6.2 years, 196 (64.3 %) were
women, and 207 (68.3 %) were caucasian. Body mass
index, previous history of stroke, use of statins were
higher in low variability group; insulin use was higher in
the high variability group. Previous history of any cardio-
vascular disease was present in 88 patients (29.4 %), but
was similar between groups. The other characteristics
were similar in both groups.
Office BP recordings and 24 h-ABPM parameters
are presented in Table 2. Systolic BP was 6.1 mmHg
(P = 0.006) higher in the high variability as compared
to the low variability group, as well as mean and daytime
SBP of 24 h-ABPM (P = 0.019 and P < 0.001, respectively).
The time-rate index of 24 h-SBP was higher in the high
variability group as compared to the low variability group
(0.648 mmHg/min vs 0.459 mmHg/min, respectively;
P < 0.001), such as the other parameters of variability,
SD SBP (13.76 mmHg vs 11.37 mmHg, respectively)
and CV of SBP (10.99 % vs 8.89 %, respectively) were
higher in the group of high variability when compared to
the group of low variability.
Echocardiographic measurements are presented in
Table 3. From the total sample, 178 patients (58.4 %)
had ventricular hypertrophy considering a cut-off point
of 1 cm. When stratified by gender and considering the
threshold values for the population of Porto Alegre [22]
the proportions were 93.6 % and 95.9 % for men and
women, respectively. Considering de diastolic function
and the cut-off point >8 for the E/E’ ratio, 234 patients
(76.8 %) showed abnormal values [21].
The time-rate index of SBP was not associated with
the echocardiography’s variables in multiple linear model
when adjusting for age, 24 h-SBP, duration of diabetes
(years) and HbA1c (Table 4). The multiple linear regres-
sion model revealed that the significant and independent
determinants for septum thickness, RWT and PW thick-
ness (parameters of left ventricular hypertrophy) were:
age (p = 0.025; p = 0.010; p = 0.032, respectively) and
24 h-SBP (p < 0.001 in the three parameters). Consider-
ing the parameters of diastolic function, age was the only
variable that was significantly associated with isovolu-
metric relaxation time (IVRT) and E/E’ ratio.
The other variability parameters were also analyzed,
but also showed no significant differences between low
and high variability groups.
Table 2 Office blood pressure recordings and ambulatory blood pressure monitoring parameters of the participants according to
blood pressure variability
Total sample Low variability High variability P
(n = 305) (n = 148) (n = 157)
Office SBP (mmHg) 143.0 ± 19.3 139.9 ± 17.5 146.0 ± 20.6 0.006
Office DBP (mmHg) 82.0 ± 10.6 81.4 ± 10.6 82.6 ± 10.7 0.355
24 h-ABPM SBP (mmHg) 130.6 ± 16.9 128.3 ± 14.7 132.9 ± 18.6 0.019
24 h-ABPM DBP (mmHg) 76.5 ± 9.3 75.7 ± 10.0 77.3 ± 8.6 0.144
Daytime 24-ABPM SBP (mmHg) 133.7 ± 15.9 130.5 ± 14.5 136.9 ± 16.7 <0.001
Daytime 24-ABPM DBP (mmHg) 78.9 ± 10.0 77.9 ± 10.4 79.9 ± 9.7 0.080
Nighttime 24-ABPM SBP (mmHg) 124.0 ± 18.3 122.6 ± 18.4 125.5 ± 18.2 0.169
Nighttime 24-ABPM DBP (mmHg) 69.6 ± 10.7 69.8 ± 11.2 69.5 ± 10.4 0.817
Time-rate index SBP (mmHg/min) 0.557 ± 0.116 0.459 ± 0.058 0.648 ± 0.075 <0.001
SD SBP (mmHg) 12.60 ± 4.40 11.37 ± 4.24 13.76 ± 4.25 <0.001
CV SBP (%) 9.97 ± 6.29 8.89 ± 3.16 10.99 ± 8.10 0.003
The comparison groups were defined by the median of time-rate index of 24 h systolic BP and classified as low and high variability of time-rate index: values ≤ 0.54
or≥ 0.55, respectively
BP blood pressure, ABPM ambulatory blood pressure monitoring, SBP systolic blood pressure, DBP diastolic blood pressure, SD SBP standard deviation of mean
SBP, CV SBP coefficient of variability SBP
Data are expressed as mean ± standard deviation. Comparisons (low variability vs. high variability) were tested by Student t test
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Discussion
The results of this cross-sectional study in a sample of
hypertensive-diabetic patients did not show associations
between BP variability assessed through 24 h-ABPM with
echocardiographic variables related to diastolic function,
left ventricular hypertrophy and cardiac chamber diame-
ters. The variables significantly associated with parameters
of left ventricular hypertrophy (septum thickness, RWT
and PW thickness) and diastolic function (IVRT and E/E’)
were age and 24 h-SBP, and the only parameter associated
with diastolic function (IVRT and E/E’) was age.
Cross-sectional and longitudinal studies showed a posi-
tive association between BP variability and cardiovascular
risk in pure hypertensive patients. The identification of
higher risk patients through variables beyond the absolute
values of BP could have practical applications. High risk
patients with high BP variability could be chosen to have
lower BP targets. Moreover, there is some evidence of a
class difference effect between antihypertensive drugs in
the within-individual visit-to-visit variability of BP. This
potential effect on BP variability could be the guide to an
optimal antihypertensive treatment in higher risk patients
[26]. In a prospective study, Zis et al. [13] reported that
patients with higher 24 h rates of SBP variation
assessed by the time-rate index were more likely to
have a negative neurologic outcome at 1 year after
stroke. Moreover, a cross-sectional study with 539 sub-
jects showed an independent association between time-
rate index of 24 h-SBP and intima-media thickness of
the carotid measured by ultrasound [9]. However, the
authors did not define the cutoff points of BP variability
normality. In another cross-sectional study 24 h-BP
variability of SBP was independently associated with
impaired renal function [12].
The association of time-rate index of SBP with
echocardiographic parameters was previously studied
by Zakopoulos et al. in a cross-sectional study. They
demonstrated that a 0.1 mmHg/min increase in the
Table 3 Echocardiographic parameters of the participants according to blood pressure variability
Total sample Low variability High variability P
(n = 305) (n = 148) (n = 157)
Cardiac chamber diameters
Aorta (cm) 3.16 ± 0.36 3.17 ± 0.37 3.14 ± 0.34 0.383
Left atrium (cm) 3.80 ± 0.45 3.83 ± 0.46 3.77 ± 0.42 0.238
LVSD (cm) 2.99 ± 0.40 2.99 ± 0.42 2.99 ± 0.39 0.898
LVDD (cm) 4.58 ± 0.47 4.61 ± 0.47 4.55 ± 0.46 0.291
Right ventricle (cm) 2.15 ± 0.28 2.16 ± 0.27 2.13 ± 0.28 0.470
LVEF (%) 64.66 ± 5.27 64.90 ± 5.09 64.42 ± 5.44 0.856
Left ventricular hypertrophy
RWT 0.43 ± 0.08 0.43 ± 0.09 0.43 ± 0.07 0.780
Septum thickness (cm) 1.00 ± 0.17 1.00 ± 0.18 0.99 ± 0.16 0.676
PW Thickness (cm) 0.95 ± 0.15 0.95 ± 0.15 0.95 ± 0.15 0.683
LVMI (g/m2) 99.19 ± 30.24 100.38 ± 32.24 98.08 ± 28.33 0.513
LAVI (mL/m2) 29.14 ± 9.98 29.32 ± 10.64 28.97 ± 9.34 0.497
Diastolic function
E wave velocity (m/s) 0.98 ± 0.18 0.97 ± 0.20 0.99 ± 0.16 0.494
A wave velocity (m/s) 0.82 ± 0.23 0.82 ± 0.24 0.82 ± 0.23 0.976
E wave DT (m/s) 235.28 ± 44.16 233.07 ± 45.26 237.37 ± 43.13 0.397
A wave length (cm/s) 179.15 ± 42.30 176.44 ± 42.15 181.71 ± 42.41 0.292
E/A ratio (m) 0.95 ± 0.30 0.94 ± 0.28 0.95 ± 0.33 0.795
E’ wave velocity (m/s) 0.07 ± 0.03 0.07 ± 0.01 0.08 ± 0.04 0.387
E/E’ ratio 11.10 ± 3.66 11.22 ± 4.08 10.99 ± 3.22 0.586
IVRT (m/s) 109.22 ± 18.15 109.42 ± 19.11 109.04 ± 17.24 0.855
The comparison groups were defined by the median of time-rate index of 24 h systolic BP and classified as low and high variability of time-rate index: values ≤ 0.54
or≥ 0.55, respectively
LVSD left ventricular systolic diameter, LVDD left ventricular diastolic diameter, LVEF left ventricular ejection fraction, RWT relative wall thickness, PW posterior wall,
LVMI left ventricular mass index, LAVI left atrial volume index, IVTR isovolumetric relaxation time, DT E wave deceleration time, BP blood pressure
Data are expressed as mean ± standard deviation. Comparisons (low vs. high variability) were tested by Student t test
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daytime rate of SBP variation was associated with an in-
crement of 7.087 g (95 % confidence interval 4.775–9.399)
in the left ventricular mass [27]. Short-term BP variability
can be estimated through different indexes derived from
24 h-ABPM. Mena et. al in a longitudinal study with 312
hypertensive patients identified an independent relation-
ship between the “average real variability index”, an index
that also averages the absolute differences of consecutive
measurements, and cardiovascular events. This positive
relationship was not identified with the SD of the mean
SBP [28]. Despite these evidences, guidelines do not rec-
ommend the use of BP variability parameters for routine
clinical use in hypertensive patients, mainly because the
lack of threshold values of BP variability and the absence
of evidences of any intervention effect [7, 29].
Diabetes is associated with higher values of short-term
BP variability [30]. Ozawa et al. in a prospective study
with diabetic hypertensive patients demonstrated higher
values of 24 h-SBP and DBP variability than the non-
diabetic hypertensive group (SD of mean SBP, 18.2 mmHg
vs 14.5 mmHg; p = 0.041 and SD of mean DBP, 11.5 mmHg
vs 9.6 mmHg; p = 0.042). A prospective study in patients
with type 2 diabetes has shown that nighttime BP variability
estimated by SD of the nighttime SBP and DBP was an in-
dependent predictor of future incidence of cardiovascular
events [31]. However in other reports in diabetic patients,
especially with nephropathy and sympathovagal imbalance,
there was an absence of nighttime BP falling because
of functional impairment of the autonomic nervous
system [32, 33]. Unfortunately, information on diabetic
neuropathy, which could have influenced the BP variability,
was not available in our study.
In the present study we analyzed the relationship of
short-term BP variability and echocardiographic parame-
ters in a high risk sample. Diabetic hypertensive patients
have approximately twice the risk of developing cardio-
vascular events when compared to purely hypertensive
patients. Moreover, 56 % of our sample had history of
previous cardiovascular disease, the median duration of
diabetes was 10 years, the mean HbA1c was 8.2 ± 1.9 %
and almost 60 % had left ventricular hypertrophy. This
high-risk profile of the subjects evaluated can explain
our negative results, as parameters of BP variability may
not add cardiovascular risk information beyond age or
BP values in such a high risk sample.
Certain limitations of the present study should be ac-
knowledged. Firstly, we quantified the rate of BP changes
using discontinuous 24 h-ABPM techniques, which cannot
adequately assess short-lasting BP fluctuations and can only
provide some insight into slow and relatively ‘long-term’ BP
oscillations. Secondly, the echocardiographic phenotypes
assessed are not in fact endpoints. However, in longitudinal
studies, these echocardiographic abnormalities have been
associated with hard outcomes. Several studies have also
confirmed the prognostic significance of left ventricular
hypertrophy and diastolic dysfunction [34, 35]. Therefore,
the detection and quantification of these echocardiographic
variables seems to be relevant in the monitoring of target-
organ damage in diabetic hypertensive patients.
Conclusion
In conclusion, in a diabetic hypertensive high risk sample,
BP variability estimated by time-rate índex of SBP was not
Table 4 Association between time-rate index and




Time-rate SBP (mmHg/min) −0.029 0.086 0.739
Age (years) 0.004 0.002 0.025
24 h-ABPM SBP (mmHg) 0.002 0.001 <0.001
Diabetes duration (years) <0.001 0.001 0.510
HbA1c (%) 0.003 0.005 0.635
RWT
Time-rate index SBP (mmHg/min) −0.044 0.041 0.277
Age (years) 0.002 0.001 0.010
24 h-ABPM SBP (mmHg) 0.001 <0.001 <0.001
Diabetes duration (years) 0.001 0.001 0.134
HbA1c (%) 0.001 0.003 0.583
PW Thickness
Time-rate SBP (mmHg/min) 0.006 0.075 0.937
Age (years) 0.003 0.001 0.032
24 h-ABPM SBP (mmHg) 0.002 <0.001 <0.001
Diabetes duration (years) <0.001 0.001 0.591
HbA1c (%) <0.001 0.005 0.977
Diastolic function
IVRT (m/s)
Time-rate SBP (mmHg/min) −5.243 9.248 0.571
Age (years) 0.889 0.174 <0.001
24 h-ABPM SBP (mmHg) 0.041 0.054 0.443
Diabetes duration (years) −0.139 0.130 0.284
HbA1c (%) 0.644 0.581 0.269
E/E’ ratio
Time-rate SBP (mmHg/min) 0.419 1.911 0.826
Age (years) 0.128 0.036 <0.001
24 h-ABPM SBP (mmHg) 0.004 0.011 0.744
Diabetes duration (years) 0.003 0.027 0.899
HbA1c (%) −0.042 0.120 0.727
BP blood pressure, SBP systolic blood pressure, ABPM ambulatory blood pressure
monitoring, HbA1c glycated hemoglobin, RWT relative wall thickness,
PW posterior wall, IVRT isovolumetric relaxation time. Adjusted for age,
24 h-ABPM-hour ABPM SBP, duration of diabetes (years) and HbA1c
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independently associated with echocardiographic parame-
ters of left ventricular hypertrophy or diastolic function.
The use of BP variability for risk stratification beyond the
absolute level of BP in this clinical setting should be ques-
tioned. Prospective studies in diabetic hypertensive patients
with hard outcomes could better confirm our findings.
Abbreviations
24 h-ABPM: 24 h ambulatory BP monitoring; BMI: body mass index; BP: blood
pressure; CV: coefficient of variation; DBP: diastolic BP; HbA1c: glycated
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thickness; SBP: systolic BP; SD: standard deviation.
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